Mutations in the androgen receptor (AR) gene result in a wide range of phenotypes of the androgen insensitivity syndrome (AIS). Inter-and intrafamilial differences in the phenotypic expression of identical AR mutations are known, suggesting modifying factors in establishing the phenotype.
AR, AR expression levels, and the phosphorylation pattern of the AR on hormone binding were identical in both siblings. However, 5␣-reductase 2 activity was normal in genital skin fibroblasts from the phenotypic male patient but undetectable in genital skin fibroblasts from the phenotypic female patient. The lack of 5␣-reductase 2 activity was due to absent or reduced expression of 5␣-reductase 2 in genital skin fibroblasts from the phenotypic female patient. Exon and flanking intron sequences of the 5␣-reductase 2 gene showed no mutations in either sibling. Additional intragenic polymorphic marker analysis gave no evidence for different inherited alleles for the 5␣-reductase 2 gene in the two siblings. Therefore, the absent or reduced expression of 5␣-reductase 2 is likely to be additional to the AIS.
Distinct phenotypic variation in this family was caused by 5␣-reductase 2 deficiency, additional to AIS. This 5␣-reductase deficiency is due to absence of expression of the 5␣-reductase iso-enzyme 2 as shown by molecular studies. The distinct phenotypic variation in AIS here is explained by differences in the availability of 5␣-dihydrotestosterone during embryonic sex differentiation. (J Clin Endocrinol Metab 86: 1240 -1246, 2001) A NDROGEN INSENSITIVITY SYNDROME (AIS) is an X-linked disorder of male sexual differentiation, caused by a defective or absent androgen receptor (AR; reviewed in Ref. 1) . Mutations in the AR gene result in a wide range of AIS phenotypes. The phenotypic spectrum in 46,XY individuals ranges from a complete female phenotype with testes [complete AIS (CAIS)], through female phenotypes with clitoromegaly or posterior fusion of the labia minora, to a male phenotype with hypospadias and/or micropenis and gynaecomastia, or even a normal male phenotype with infertility, all defined as partial AIS (PAIS) (1) . The finding of more than 150 different AR gene mutations in over 250 AIS patients (2) illustrates the genetic heterogeneity in AIS.
The AR is a transcription factor that binds either testosterone (T) or 5␣-dihydrotestosterone (DHT); however, DHT is bound with higher affinity and has a slower dissociation rate from the receptor than T (3) (4) (5) . When androgen is bound to the AR, the complex dimerizes and migrates into the nucleus where it recruits transcription factors and binds to the promoter region of androgen-sensitive target genes (6) .
With the advent of molecular analysis of the AR gene it was hoped that a correlation between a molecular defect and a particular phenotype could be established. Such a relationship would enable prediction of the response to androgen therapy in infants with PAIS, relevant for not only long-term psychosexual outcome but also for genetic counseling of parents and other identified female carrier relatives. Ten years after cloning of the AR gene (7) (8) (9) (10) , it is obvious that there is no simple genotype-phenotype relationship in this phenotypically and genotypically heterogeneous syndrome. Identified mutations are associated with different phenotypes in the same kindred (11) (12) (13) (14) or rarely with CAIS in one kindred and with PAIS in another (2) . Therefore, additional factors apparently may influence the effect of the mutant receptor on the development of the external genitalia.
Reduced 5␣-reductase 2 activity has been described in the 70s and 80s in AIS families and has been suggested to be the cause of the observed phenotypic variation (15) (16) (17) . At that time, molecular evaluation of the AR and 5␣-reductase 2 genes was not yet available.
Here, a family with distinct phenotypes in two siblings with the same AR gene mutation is reported. The identified mutation in the AR gene, R846H (amino acid numbering based on 20 glutamine residues and 16 glycine residues, thus a total of 910 amino acids) is a frequently identified mutation (2) . Experimental evidence is provided for a different availability of DHT in these two siblings.
Subjects and Methods
In a nationwide study on the genotype/phenotype relationship in AIS, we studied a family with eight children, of whom two were affected with AIS (Fig. 1) . The parents (subjects I-1 and I-2; Fig. 1 ) were of Moroccan descent and first cousins: their fathers were brothers. There was no family history of ambiguous genitalia.
Subject II-5 was a 13-yr-old pubertal female patient, with not yet fully developed breasts, few pubic hairs, and no axillary hair (Tanner stage M3, P2, A0), a female habitus, and female voice. She was studied after her brother was diagnosed with AIS. The karyotype was 46,XY. External genitalia were a normally sized clitoris, normal labia majora, posterior fusion of the labia minora leading to an urogenital sinus ( Fig. 2A) , and a shallow (2.5 cm in length), blindly ending vagina that was connected with the urogenital sinus. Testes were localized bilaterally in the inguinal region. The following serum levels of hormones were determined: T, 13. In accordance with her personal wish, she was not gonadectomized until 2 yr later, at age 15.5 yr. Normally developed epididymides and vasa deferentia were found. Mü llerian duct derivatives were absent. Serum hormone levels at that time were: T, 31.5 nmol/L; DHT, 2.42 nmol/L; T/DHT, 13; estradiol, 156 pmol/L; and LH, 8.4 U/L. Her voice had remained high-pitched, the clitoral size remained normal, pubic hair had remained Tanner stage P2, axillary hair was still absent, and her breasts had grown to M4. T and DHT, measured every 6 months from age 13.5 yr, showed T/DHT ratios between 8.6 and 13.0. From age 14, T had been above 30 nmol/L. Subject II-8 ( Fig. 1) , karyotype 46,XY, was born with perineoscrotal hypospadias, a micropenis with well developed corpora cavernosa, a bifid scrotum containing testes, and transposition of the scrotum (Fig.  2B) . Mü llerian duct remnants were absent, as was established by ultrasound. Bilaterally epididymides were palpable. Serum hormone levels measured at age 4 days: T, 0.64 nmol/L. Seventy-two hours after 1500 U human CG (hCG) im, T was 18 nmol/L. He was assigned the male sex. At 5 yr of age his basal serum levels were: LH, 0.1 U/L; T, 0.1 nmol/L; and DHT, Ͻ0.1 nmol/L. Seventy-two hours after 1500 U hCG im: T, 11.8 nmol/L; DHT, 2.1 nmol/L; T/DHT, 5.6. All values are within the normal range for this age.
I-1 and II-3 were normally virilized healthy adult males. II-6 was a normal healthy prepubertal boy with a normal penis length and a normal testis volume for his age. The mother, subject I-2, had a gonadal/ somatic mosaïcism for the AR mutation as was shown by segregation analysis of the different AR alleles among affected and nonaffected family members and by allele-specific oligonucleotide analysis, respectively, as described previously (18) .
The medical ethical committee of the University Hospital Rotterdam approved the protocol of this study.
SHBG suppression test
Androgen sensitivity in the liver can be measured in vivo with use of an SHBG suppression test. We have used the protocol described by Sinnecker et al. (19) : Stanozolol (0.2 mg/kg/day, single evening dose) was administered orally at days 0, 1, and 2. Blood samples were taken before and at days 5, 6, 7, and 8 after the start of the test. The initial SHBG serum level was compared with the lowest level obtained after administration of Stanozolol (days 5, 6, 7, and 8) and expressed as a percentage of the initial value. In normal controls the SHBG serum level after Stanozolol declined to 35.6 -62.1% (range) of the initial value. However, in patients with CAIS, the SHBG serum level remained unchanged, and in PAIS patients the SHBG level declined to 48.6 -89.1% (range) of the initial value (19) .
AR gene mutation detection
Genomic DNA was isolated from peripheral blood leukocytes and from cultured genital skin fibroblasts, following standard procedures (20) .
Exon and flanking intron sequences were screened for mutations in the AR gene with the use of PCR-single-strand conformational polymorphism (21) . PCR fragments suspected to harbor mutations were analyzed by direct sequencing (22) . Furthermore, in DNA isolated from genital skin fibroblasts, the entire AR gene of subject II-5 was sequenced.
AR gene CAGn(CAA)/GGN repeat length
CAGn(CAA) and GGN repeat lengths in exon 1 of the AR gene, encoding poly-glutamine and poly-glycine stretches, respectively, were determined as described previously (21, 22) .
Cell culture
Skin biopsies were taken either during surgical correction of the external genitalia, or gonadectomy or circumcision. Genital skin fibroblasts were derived from biopsies of the fusion line of the labia minora of subject II-5 of control individuals, and from scrotal skin of subject II-8 and from preputium of a normal prepubertal boy obtained at circumcision. Furthermore, genital skin fibroblasts were analyzed from biopsies from preputium of a prepubertal 5␣-reductase 2-deficient patient with clitoromegaly and posterior fusion of the labia minora. This patient had a T/DHT ratio after hCG of 16.5. All cell lines were cultured as described previously (22), with modifications as described with the experiments.
Androgen characteristics of the AR
Whole cell Scatchard analysis was performed on genital skin fibroblasts, as described previously (22) . Genital skin fibroblast (GSF) 1 was used from subject II-5.
SDS-PAGE of the AR
Confluent cell layers in 150 cm 2 culture flasks, were cultured in serum-free medium for 24 h, followed by 24 h in medium containing increasing concentrations (0, 5, 30, and 100 nm) of the synthetic, nonmetabolizable androgen methyltrienolone (R1881). GSF 1 was used from subject II-5. Whole cell lysates were prepared, immunoprecipitated, separated on a SDS-PAGE gel, and immunostained as described previously (22) . 
5␣-Reductase 2 assay
5␣-Reductase 2 activity can be influenced by either clonal origin of the cell line (23) or by the site of origin of the biopsies (24) . Therefore, two different GSF cell lines from subject II-5 (GSF 1 and 2) derived from separate biopsies taken 1.5 yr apart were used for the studies.
GSF cell lines derived from biopsies from subject II-8, from a normal male, from a normal female, and from a 5␣-reductase 2-deficient patient homozygous for a known pathogenic mutation in the 5␣-reductase 2 gene (H231R) were used as controls.
Because 5␣-reductase 2 activity increases with serial subcultures (25, 26) , all cell lines used were the seventh subculture.
To reduce possible bias by confluency rate, all cell lines were grown in 75-cm 2 culture flasks with medium containing 10% FCS. They were harvested 7 days after subculture. At that time, the cell lines were confluent and the flasks contained ϳ1.2 ϫ 10 6 cells.
Harvesting of cells. Cells were washed multiple times with PBS and with 20 mm Tris saline (pH 7.4), then scraped in Tris saline and pelleted at 800 ϫ g. Pellets were washed twice in Tris saline. Cell-free extracts were prepared by four cycles of freezing in liquid nitrogen and thawing.
Enzyme assay. Forty microliters of cell-free extracts were incubated with 10 l of 30 mm NADPH and 50 l reaction mixture [reaction mixture consisted of 500 l of 10 mm Tris citrate (pH 5.5), 2.4 pmol 1,2,6,7 3 H-testosterone (Amersham Pharmacia Biotech, Little Chalfont, UK), and 7.6 pmol testosterone (Steraloids)] at 37 C for 1 h. The reaction was stopped on ice. Each incubation was done in duplicate. Assays were done in triplicate.
To all samples 10 l of a steroid mixture containing androstanedione, androstenedione, DHT, testosterone, 3␣-androstanediol, each 1 mg/mL ethanol, were added, before extraction of radioactivity with a total of 3 ϫ 500 L ethylacetate. Extracts were evaporated to dryness, and the residues were dissolved in 50 l ethanol and chromatographed in dichloromethane:ethylacetate:methanol (85:15:3) on a 0.25-mm layer silica gel plate, 20 ϫ 20 cm (Merck, Darmstadt, Germany). Steroids were visualized in a control lane by spraying with 20% H 2 SO 4 in methanol and developing at 100 C for 15 min. Fractions were collected in separate vials, resuspended in 500 l ethanol, and were counted in a liquid scintillator counter. 5␣-Reductase activity was calculated from the sum of 3 Hradioactivity in the androstanediol, DHT, and 3␣ androstanediol fractions divided through the sum of 3 H radioactivity in the androstanediol, androstenediol, DHT, T, and 3␣ androstanediol fractions. The amount of protein in each cell-free extract was determined according to Bradford (27) .
5␣-Reductase activity was expressed as femtomoles of 5␣ reduced steroids formed per milligram of protein per hour.
Analysis of the 5␣-reductase 2 gene and polymorphic marker analysis
Exon and flanking intron sequences of the 5␣-reductase type 2 gene (SRD5A2) from subject II-5 were analyzed with direct sequencing after amplification of fragments with primers described by Hiort et al. (27) . As an intragenic polymorphic marker, codon 89 in exon 1 of the SRD5A2 gene was used. This codon is either CTA or GTA with unknown allele frequencies (29, 30) . Genomic DNA isolated from GSF 1 (subject II-5) and GSF (subject II-8) was used.
RT-PCR of 5␣-reductase 2 messenger RNA (mRNA)
Total RNA was extracted from GSF cell lines using Trizol reagent (Life Technologies, Inc., Breda, The Netherlands) and quantified by absorption at 260 nm. Complementary DNA (cDNA) was synthesized from 2.5 g RNA with the use of an oligo dT primer (Promega Corp., Madison, WI). Of each investigated cell line, cell pellets from different cell culture flasks were pooled and divided in equal aliquots. RNA was isolated from these aliquots in separate experiments. The various aliquots of RNA were subjected to several independent RT-PCR experiments.
As a control for cDNA synthesis, ␤ 10 actin was used. ␤ Actin was amplified with antisense primer GAGGTAGCAGGTGGCGTTTAC-GAAGAT and sense primer AAGGATTCCTATGTGGGCGACGAG. Primers used for amplification of the 5␣-reductase 2 gene were: antisense primer 5B, 5Ј-TGACAGTTTTCATCAGCATTG-3Ј specific for 3Ј untranslated sequences in exon 5; and sense primer 120A, 5Ј-CACTG-GAAATGGAGTCCTTC-3Ј, starting at codon 120 in exon 2. These primers were used in a PCR reaction as described below.
Three microliters of the obtained cDNA reaction product was used in a 50-l PCR amplification reaction. The 50-L PCR reaction mix contained 1.5 mm MgCl 2 . Conditions for the PCR reactions in a Biometra
FIG. 2. External genitalia of subject II-5 at age 15.5 yr (A) and subject II-8 at 1 month of age (B).
cycle sequencer were: hot start at 94 C for 5 min, then 35 cycles at 94 C for 1 min, at 55 C for 30 sec, at 72 C for 1 min, and final extension for 10 min at 72 C. The PCR product was visualized after electrophoresis on a 2% agarose gel that contained ethidium bromide. Amplification of genomic DNA was prevented because intervening introns were in total ϳ 7.3 kb in size, and the Amplitaq polymerase (Perkin-Elmer Corp., Norwalk, CT) cannot amplify DNA of this size under the used conditions.
The resulting PCR product was subcloned into a plasmid using the TOPO TA cloning kit (Invitrogen, San Diego, CA) and subjected to automated sequencing.
Results

SHBG suppression test
An SHBG suppression test (19) showed a maximal decrease in SHBG of 73.5% on days 5, 6, 7, and 8 in the female patient, subject II-5 [normal males, Ͻ63.4%; PAIS, 63.4 -93%; CAIS, Ͼ92% (31)], whereas a maximal decrease of 92% on day 7 was seen in subject II-8. It can be concluded that both siblings display a suppression in the PAIS range.
Mutation detection and identification in the AR gene
With PCR-single-strand conformational polymorphism, followed by direct sequencing of the AR gene, mutation R846H in the ligand-binding domain of the AR was identified in both individuals II-5 and II-8. No other mutations were identified on sequencing of the exon and flanking intron sequences of the AR gene of subject II-5.
Length of (CAG)nCAA and GGN repeats
In both siblings the (CAG)nCAA and GGN repeats in exon 1 of the AR gene mutant-allele carried 14 glutamine and 24 glycine residues (18), respectively.
AR binding characteristics
AR binding characteristics in GSF of subjects II-5 and II-8 (Table 1) show an increased equilibrium dissociation constant (K d ) but a normal number of binding sites (B max ). The difference in B max and K d values between the two siblings should be interpreted as a variance of Scatchard analysis.
Hormone-dependent AR phosphorylation
AR protein isolated from wild-type cells cultured in the absence of androgens migrates as a doublet of 110 and 112 kDa during SDS-PAGE. These represent an unphosphorylated AR isotype and a phosphorylated AR isotype, respectively. On binding of androgens, the AR undergoes additional phosphorylation, resulting in a third isoform of 114 kDa. AR mutants that are either partially defective in ligand binding or in DNA binding or in transcription activation, migrate with a reduced amount of the 114 kDa isoform during SDS-PAGE (Ref. 31; Fig. 3 ). At a relatively low androgen concentration of 5 nm R1881, GSFs of II-5 and II-8 express equally reduced amounts of the third isoform of 114 kDa compared with the wild type. Increased androgen levels did not induce the 114-kDa band as in the wild-type cells (Fig. 3) . Moreover, both siblings have an equally deficient hormone induced upshift of the 114 kDa AR isoform. A deficient hormone induced upshift is in agreement with the increased dissociation of the AR hormone complex in GSF of both patients.
5␣-Reductase 2 activity
Of subject II-5, two different GSF cell lines were deficient in 5␣-reductase 2, similar as in a 5␣-reductase 2-deficient patient homozygous for SRD5A2 mutation H231R. However, sibling II-8 had normal 5␣-reductase 2 activity in GSF ( Table 2) .
Analysis of the 5␣-reductase 2 gene and polymorphic marker analysis
No mutations were found in the 5␣-reductase type 2 gene of subjects II-5 and II-8 on sequencing exon and flanking intron sequences.
Both siblings were heterozygous for a known polymorphism in exon 1 of the 5␣-reductase 2 gene, CTA/GTA, codon 89 (data not shown). A homozygous defect in the 5␣-reductase 2 gene, inherited from the consanguineous parents and present in other parts of the gene than the sequenced parts such as introns or in a gene promoter, is, therefore, very unlikely.
5␣-Reductase 2 mRNA expression
After RT-PCR of 5␣-reductase 2 mRNA using a primer combination, as outlined in Subjects and Methods, a 460-bp fragment can be expected. No 5␣-reductase 2 cDNA was detectable after RT-PCR of total RNA preparations from GSFs 1 and 2 of subject II-5, whereas in total RNA preparations from the GSF of subject II-8 a band of 460-bp was detected (Fig. 4) . This band was subcloned and sequenced and exhibited the wild-type 5␣-reductase 2 gene sequence. Therefore, the absence of 5␣-reductase type 2 activity in GSFs of subject II-5 is most likely due to lack of or reduced expression of 5␣-reductase type 2.
Discussion
In this family, a very different phenotypic expression of AIS is observed in siblings carrying the same mutation in the AR gene. Additional mutations in the AR gene or differences in the length of the polyglutamine or polyglycine repeats were not found. AR gene promoter mutations are very unlikely because AR protein expression is similar and normal in both siblings. Furthermore, phosphorylation of the AR on hormone binding, was equally reduced in genital skin fibro- blasts of both siblings, irrespective whether low or high concentrations of the nonmetabolizable androgen R1881 were used. Phosphorylation of the AR occurs during DNA binding of the ligand-AR complex on hormone-responsive elements and during or following transcription of androgen-regulated genes (31) . The equally reduced phosphorylation of ARs and comparable clinical androgen responsiveness in both siblings, as determined by SHBG suppression tests, provide evidence that the AR itself is not responsible for the distinct variation in phenotype and suggest an important role for factors other than the AR in determining the phenotype. 5␣-Reductase activity was found to be totally absent in genital skin fibroblasts of subject II-5 (Table 2) . DHT, formed in the embryonal urogenital tissues by 5␣-reductase 2, causes elongation and enlargement of the urogenital tubercle and fusion of the urogenital swellings and folds during the development of the embryo (32, 33) . We hypothezised that the phenotypic differences between the siblings might be due to the difference in availability of DHT, especially because both siblings carry a particular mutant AR (R846H). When this R846H mutant AR is stimulated with DHT instead of testosterone, the transcriptional deficit becomes less (34, 35) and the functional defect can even be partially corrected by the repeated addition of DHT (34) . Therefore, a difference in availability of DHT between the two siblings could have been of particular influence on the phenotype.
Although, serum dihydrotestosterone levels at puberty in subject II-5 are low but detectable and once fell within the low normal range, similar DHT serum levels are found in pubertal/adult 5␣-reductase 2-deficient patients with deficient 5␣-reductase 2 activity as established in GSFs (16, 36) . When 5␣-reductase 2-deficient patients enter puberty they start to synthesize some DHT. The source of this DHT may be either peripheral conversion by 5␣-reductase type 1 in the liver and skin or, in some cases, residual activity of the mutant enzyme.
A 5␣-reductase 2 deficiency secondary to the primary de- In all assays the recovered radioactivity represented at least 84% of the added 3 H-testosterone. All assays were done in duplicate, variation between duplicate measurements was Ͻ11%.
a Mean and range are given. Ranges in different experiments are shown.
FIG. 4.
RT-PCR of 5␣-reductase 2 mRNA. RNA extracted from GSFs 1 and 2 of subject II-5 and RNA from the GSF of subject II-8 was used. ␤ Actin expression was used as a control for cDNA synthesis. The amplified 5␣-reductase 2 cDNA fragment, 460 bp in size, is indicated with an arrow. fect AIS has been reported to cause phenotypic differences in other families with AIS and was established by 5␣-reductase 2 assays in GSFs and by hormonal analysis in serum (15) (16) (17) . It has been suggested that in AIS patients 5␣-reductase 2 enzyme activity is preserved in the liver but deficient in the periphery, in contrast to the autosomal recessive inherited syndrome of 5␣-reductase 2 deficiency wherein a generalized severe defect of both hepatic and peripheral 5␣-reductase is found (16, 37) . These observations were made before cloning of the AR and 5␣-reductase 2 genes (7, 10, 29, 38) . The nature of the decreased 5␣-reductase 2 activity remained unidentified. The repeated observation of this 5␣-reductase 2 deficiency secondary to AIS and the identification of a mutant AR, which is especially dependent on DHT for residual androgen action, provides a basis for further studies on secondary 5␣-reductase 2 deficiency.
RT-PCR experiments in this family show that the 5␣ 10 reductase 2 deficiency in GSFs of subject II-5 is due to reduced expression of the 5␣-reductase 2 gene (SRD5A2). A homozygous defect in the SRD5A2 gene inherited from the consanguineous parents was excluded as no mutations in the SRD5A2 gene were found in both siblings. The presence of mutations in the remaining intronic sequences or the promoter region of the SRD5A2 gene is very unlikely because both siblings are heterozygotes for the CTA/GTA polymorphism in exon 1.
With molecular means we show that the additional 5␣-reductase 2 deficiency in the presented subject II-5 with AIS is due to absent or reduced expression of the 5␣-reductase 2 enzyme.
The etiology of this additional 5␣-reductase 2 deficiency is not clear. One possible explanation is disruption of a feed forward control mechanism: formation of trace amounts of DHT that are bound to the AR induces 5␣-reductase 2 activity thereby increasing DHT synthesis and triggering a positive developmental cascade. Such a positive feedback mechanism exists in the rat embryonic urogenital tract where 5␣-reductase type 2 expression is increased by either T or DHT (39) . A positive feedback mechanism is also present in adult rat prostate but is absent in embryonic rat prostate (39, 40) . In humans, the presence of such a positive regulation by androgens is suggested by the presence of reduced 5␣-reductase 2 expression in urogenital swellings and tubercles in female fetuses. The expression of 5␣-reductase 2 in female fetuses is one third of the expression of 5␣-reductase 2 found in males, who have higher levels of androgens (36) . Arguments against positive regulation of 5␣-reductase 2 enzyme activity in humans are the observations that in many CAIS patients 5␣-reductase 2 activity is normal and during in vitro culture of GSFs no increase of 5␣-reductase activity is observed after stimulation with androgen (24, 41, 42) . In GSFs, 5␣-reductase 2 is the predominantly expressed and active iso-enzyme (43) .
Others have suggested a unbalance between estrogen and androgen action as the cause for secondary 5␣-reductase deficiency (16, 24) .
An interesting possibility is an additional autosomal recessively inherited defect in a factor regulating 5␣-reductase 2 expression, inherited from the consanguineous parents by subject II-5. Because 5␣-reductase 2 expression appears in fetal rats before testicular androgen synthesis starts, it was suggested that the early regulation and most likely the initial induction events are androgen independent in rat (38) . Which factors control the temporal and cell type-specific pattern of 5␣-reductase enzymes in the rat or in man is presently unknown.
These observations support the hypothesis that differences in the availability of DHT in different target tissues could lead to phenotypic variation between AIS patients who carry the same AR gene mutation. This study shows that distinct intrafamilial phenotypic variation can be associated with additional 5␣-reductase 2 deficiency, information to be implemented in genetic counseling of families with androgen insensitivity.
Additional 5␣-reductase 2 deficiency was shown to be associated with undetectable 5␣-reductase 2 mRNA levels in GSFs. The total lack of enzyme activity is unlikely to be due to mutations in the 5␣-reductase 2 gene itself. Possible causes for this additional 5␣-reductase 2 deficiency are a defective autocatalyic regulation or an autosomal recessively inherited defect in a regulatory protein that controls the cell typespecific and temporal expression pattern of the 5␣-reductase 2 gene.
